AIQ Solutions is a commercial-stage imaging biomarker company with offices in Madison, Wisconsin, and Perth, Australia. AIQ’s software technologies analyze medical scans from all imaging modalities and radiotracers to support more efficient go/no-go decisions and optimize clinical trial patient selection. It quantifies lesion-specific treatment response heterogeneity which drives clinical outcome and predicts organ-specific toxicity risk.

AIQ Score, a single patient-level metric that uses full patient lesion analytics, allows early prediction of optimal vs suboptimal responders to therapy.

AIQ Solutions was born out of the University of Wisconsin Translational Imaging Research Program. The founders, Robert Jeraj, Ph.D.; Glenn Liu, MD; George Wilding, MD; and Dona Alberti, BSN, RN, worked together for over ten years at the University of Wisconsin Carbone Cancer Center with decades of combined experience in drug development, clinical trials, and translational imaging research.

In January 2015, AIQ was incorporated. The patents protecting AIQ’s innovations were issued in October 2015 and March 2017. In April 2017, AIQ signed an exclusive license agreement with the Wisconsin Alumni Research Foundation covering both patents. In 2021, AIQ established its first oversea office in Perth, Australia. AIQ’s technology has been cleared for clinical use under 510(k) as a medical device class II and completed Medical Device Single Audit Program (MDSAP) certification and ISO – 13485:2016 audits.